Skip to content

Stryker SYK Acquisitions

Acquisitions at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.04B+304,000%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$1M0.0%
Boston Scientific logo
Boston ScientificBSX
$523M+119%
Intuitive Surgical logo
Intuitive SurgicalISRG
$528.2M
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$166.9M+4.3%
Globus Medical logo
Globus MedicalGMED
$4.91M-1.8%

Other financials

Income statement

See full
Revenue$6.0B+2.6%
Gross profit$3.8B+1.8%
Operating income$936.0M+11.8%
Net income$745.0M+13.9%
EPS (diluted)$1.93+14.2%

Balance sheet

See full
Cash & equivalents$2.9B+24.1%
Total debt$14.4B-15.1%
Total assets$46.3B+0.6%

Cash flow

See full
Operating cash flow$581.0M+132%
CapEx$166.0M+35.0%
Free cash flow$415.0M+227%

Valuation

See full
Market cap$120.7B-19.1%
Enterprise value$132.2B-19.2%
P/E36.2×-15.0×
P/S4.8×-1.5×

Profitability

See full
Gross margin63.8%-0.1pp
Operating margin19.7%+4.4pp
Net margin13.2%+0.9pp
FCF margin18.1%+2.7pp

Returns & leverage

See full
Return on equity32.8%
Debt / equity0.8×
Current ratio2.1×+0.5×

Where this comes from

Reported directly by Stryker in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired.

The official record: Stryker’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stryker's acquisitions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stryker's acquisitions?
Stryker (SYK) reported acquisitions of $22M in Q1 2026.
How has Stryker's acquisitions changed year-over-year?
Stryker's acquisitions decreased by 99.5% year-over-year, from $4.75B to $22M.
What is the long-term trend for Stryker's acquisitions?
Over 2 years (2021 to 2025), Stryker's acquisitions has grown at a 282.5% compound annual growth rate (CAGR), from $339M to $4.96B.
What does acquisitions mean?
Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.